To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025.
JMCP Findings: ER+/HER2− Metastatic Breast Cancer
FINDINGS FROM THE AMCP MARKET INSIGHTS PROGRAM | October 2025
Breast cancer is the most common cancer diagnosed in women in the United States, and its impact on both patients and their caregivers, particularly in advanced disease, is substantial. The treatment and care of the most common subtype of breast cancer is rapidly changing, which can be challenging for health care organizations. However, these organizations need to stay current on updates in breast cancer to better support patients and caregivers.
To discuss navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025.
For more disease state research, view the Market Insights Program.
Related
Read the Journal of Managed Care + Specialty Pharmacy (JMCP) - November 2025 Issue
AMCP developed this first-of-its-kind report focused on the managed care pharmacy workforce. The objectives of this report are threefold: to describe the composition of the workforce, to serve as a valuable resource f or individuals and organizations, and to capture pharmacists’ perspectives on key workforce-related issues. The 2025 Managed Care Pharmacy Workforce Report represents a significant step toward a deeper understanding of the managed care pharmacy landscape.
Featured News & Resources
See Full Calendar
Webinars
AMCP eLearning Day: Nexus Encore
National Meetings
AMCP 2026 Registration Opens
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
